Study title: A randomised, double-blind, double-dummy, parallel-group, multicentre, phase-III study to investigate the effect of Symbicort® Turbuhaler® (budesonide/formoterol) 1280/36 µg total delivered dose in the treatment of acute asthma compared with Oxis® Turbuhaler® (formoterol) 36 µg total delivered dose in adolescent and adult patients not responding adequately to β2-agonists
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Respiratory Tract Diseases [C08] | |||||
| Brands: | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: BUDESONIDE AND FORMOTEROL | |||||
| ATC code: | |||||
| Document link: D5896C00005 CSR Synopsis.pdf | |||||
| Document date: 2011-09-15 | |||||
| Study number: D5896C00005 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | Y | |